CGEM

Cullinan Therapeutics, Inc.

A clinical-stage biopharmaceutical company in Cambridge, Massachusetts that develops experimental therapies for cancer and autoimmune diseases, advancing drug candidates it discovers or licenses through early clinical trials. Founded in 2016 as Cullinan Pharmaceuticals, it rebranded to Cullinan Therapeutics in 2024 to signal its shift beyond oncology into autoimmune conditions. Its name nods to the Cullinan Diamond, the largest gem-quality rough diamond ever found, evoking rarity and brilliance.

CUSIP: 230031106HealthcareUS1 holder

Ownership Activity Financials Filings

CGEM

CGEM

Regulation FD Disclosure

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Regulation FD Disclosure

Regulation FD Disclosure

Regulation FD Disclosure

Results of Operations and Financial Condition

Results of Operations and Financial Condition